SEC Filing Summary: Flex Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Flex Pharma, Inc. on October 30, 2017. The registrant is a Delaware corporation headquartered in Boston, MA. The filing reports a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in corporate leadership and does not contain financial performance data.
Material Changes
On October 30, 2017, the Board of Directors unanimously voted to increase the Board size to ten members. Roger Tung was elected to the Board effective immediately as a Class II member, serving until the 2020 annual meeting of stockholders or until his successor is elected.
Management Commentary and Compensation
There are no arrangements or understandings between Dr. Tung and any other person regarding his election. Dr. Tung will receive compensation in the same manner as other non-employee directors, with details available in the Company's 2017 Proxy Statement. In connection with his appointment, Dr. Tung entered into the Company's standard Indemnity Agreement.
Investor Verification Checklist
- Verify the updated Board composition and Class II term expiration date (2020).
- Review the 2017 Proxy Statement for specific director cash and equity compensation details.
- Confirm the filing of the Indemnity Agreement as Exhibit 10.1 to the referenced S-1 Amendment.
- Note that this filing contains no financial results or operational updates.